# Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

> **NCT02834507** · PHASE2 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 19 (actual)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **DRUG:** Placebo
- **DRUG:** BIA 3-202
- **DRUG:** Comtan®
- **DRUG:** Sinemet®

## Key facts

- **NCT ID:** NCT02834507
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2016-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02834507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02834507, "Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02834507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*